Clinical characteristics and outcomes of patients with venous thromboembolism receiving edoxaban...

T Hara, M Sata - Circulation Journal, 2024 - jstage.jst.go.jp

Anticoagulant therapy is a drug therapy that inhibits the formation of blood clots. Although
anticoagulants are effective in preventing thromboembolism, they also carry the risk of …

Arg-Specific serine Protease-Targeted edoxaban tosylate monohydrate-Poly (lactic-co-glycolic acid) Nanoparticles: Investigating Stuart-Prower factor targeting and …

P Pazhani, JP Dharmian, S Arumugam… - European Journal of …, 2024 - Elsevier

The goal of the current study was to formulate and examine the potential of poly (lactic-co-
glycolic acid)(PLGA) as carriers to facilitate the targeted administration of edoxaban tosylate …

Edoxaban enfolded beta-1,4-poly-d-glucosamine nanoparticles for targeting eponym Stuart–Prower factor for treatment of venous thrombosis

P Pazhani, JP Dharmian, S Arumugam… - Journal of Drug …, 2024 - Taylor & Francis

The present research looked for ways to develop shielded nanoparticles (NPs)-drug
transporters made of chitosan (CS) to enhance the bioavailability of edoxaban tosylate …

Unapproved Dose of Direct Oral Anticoagulants for Venous Thromboembolism―Right or Wrong?―

S Adachi, T Adachi, Y Nakano - Circulation Journal, 2024 - jstage.jst.go.jp

Figure. Differences between Japan and the USA and Europe in recommended doses of
each direct oral anticoagulant for adult patients with venous thromboembolism (VTE) …

Temporal Trends in Management Strategies and Clinical Outcomes of Venous Thromboembolism in Post Direct Oral Anticoagulants Era from 2017 to 2023

W Xiong, Y Yamashita, T Fukasawa, C Takeda… - Available at SSRN … - papers.ssrn.com

Temporal Trends in Management Strategies and Clinical Outcomes of Venous Thromboembolism
in Post Direct Oral Anticoagulants Era Page 1 Temporal Trends in Management Strategies and …